Key Slides on Hepatitis B Pretreatment Evaluation

Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Paul Y. Kwo, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.49 MB
Released: February 16, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from:
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert Dr. Yasuhito Tanaka on HCC risk prediction in patients with chronic hepatitis B using the novel serum biomarker HBcrAg

person default Yasuhito Tanaka, MD, PhD Released: May 6, 2021

Brief presentation by Dr. Anna Christina dela Cruz on the various methods to assess liver inflammation and fibrosis and translating results into practice from Clinical Care Options (CCO)

Anna Christina L. dela Cruz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: April 19, 2022

Download free slides reviewing key data and AASLD guidance on methods to evaluate liver fibrosis and inflammation in patients with HBV infection

Anna Christina L. dela Cruz, MD Released: April 20, 2021

W. Grace L. H. Wong 博士,来自 Clinical Care Options (CCO)的慢性 HBV 患者的 HCC 风险评估和跨学科管理

Grace LH Wong, 医学博士 Released: April 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.